N/A N=72 Randomized Single-blind Treatment

Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol

Anxiety Disorders · Depression · Posttraumatic Stress Disorder

Bottom Line

View on ClinicalTrials.gov: NCT04912089 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jul 2025

Primary outcome: Primary: Change in Cognitive Performance — 4.92; 8.18; .27 score on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: COGENT (Behavioral)
Age: Adult · 21+ yrs
Sex: All
Sponsor: University of California, San Diego
Primary completion: May 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Cognitive Performance	4.92; 8.18; .27	—
SECONDARY Change in Reading Span Blood Oxygen Level Dependent (BOLD) Response	-2.90; -2.16; 2.46	—
SECONDARY Change in Emotional Working Memory Blood Oxygen Level Dependent (BOLD) Response	.21; .58; -1.56	—
SECONDARY Change in Neuropsychological Performance	4.35; 7.94; 1.37	—
SECONDARY Anxiety Symptoms	-1.21; -4.28; -1.14	—
SECONDARY Symptoms of Depression	-2.46; -1.56; -1.48	—
SECONDARY PTSD Symptoms	-6.46; -4.39; -7.91	—
SECONDARY Change Repetitive Negative Thinking (RNT)	-.09; -.12; .01	—
SECONDARY Self-reported Attention Attention	-.04; 1.89; 1.05	—
SECONDARY Emotion Regulation	-1.04; -1.06; .59	—
SECONDARY Disability	-1.66; -1.42; -.32	—
SECONDARY Suicide Cognitions	-2.79; -5.44; -5.18	—
SECONDARY Alcohol Use	.17; -.17; .14	—
SECONDARY Drug Abuse	.00; .11; -.09	—
SECONDARY Insomnia	-.21; -3.06; -2.09	—
SECONDARY Change in Mood and Emotions: Negative Affect	-3.38; -5.06; -.38	—
SECONDARY Change in Mood and Emotion: Positive Affect	1.25; 2.55; .32	—

Summary

The proposed project aims to test the cognitive and neural effects of a cognitive training in a sample of individuals seeking treatment for anxiety, depression, or traumatic stress symptoms. Participants will be randomly assigned to a high dose, low dose, or assessment only condition. Participants will be compared on cognitive performance and brain response during cognitive tasks from baseline to post-treatment.

Eligibility Criteria

Inclusion Criteria

age 21-55
fluent in English
diagnosis of mood, anxiety, or traumatic stress disorder
clinically elevated repetitive negative thinking
outpatient status
6-week stability if taking selective serotonin reuptake inhibitor (SSRI) medications

Exclusion Criteria

past year diagnosis of severe alcohol or moderate or greater substance use disorder
lifetime history of psychotic or bipolar I disorder
acute suicidality necessitating immediate clinical intervention
neurodegenerative or neurodevelopmental disorders
history of moderate or severe traumatic brain injury or other known neurological condition
sensory deficits that would preclude completing tasks
conditions unsafe for completing MRI scanning (e.g., metal in body)
currently receiving psychosocial treatment
currently receiving psychiatric pharmacotherapy, except SSRIs

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04912089). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.